Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Questions of the Month

PlayWhat does the future hold for CRISPR base editing of PCSK9?

What does the future hold for CRISPR base editing of PCSK9?

Kiran Musunuru, Professor and Genetics Researcher at University of Pennsylvania, USA discusses the prospects for a one-shot “vaccination” against heart attacks, the leading cause of death worldwide. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing has evolved rapidly to allow for testing in a…

read more »
PlayWill evinacumab eliminate the need for LDL-apheresis in patients with homozygous FH?

Will evinacumab eliminate the need for LDL-apheresis in patients with homozygous FH?

Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) gives his view. Evinacumab is a remarkable therapy for individuals with homozygous familial hypercholesterolaemia (HoFH) and can result in a further 60% reduction in LDL cholesterol levels on top of aggressive lipid lowering therapy (1)….

read more »
PlayLDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?

INTENSITY-HIGH: Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease The landmark PCSK9 inhibitor trials – FOURIER and ODYSSEY OUTCOMES – established the cardiovascular benefits of lowering LDL cholesterol to very…

read more »